BAX and neoplasm: The tumor-specific immune response has been compromised in cases where p53, BAX, and/or caspase 8 is mutated, as well as when autophagy-related genes needed for MTX/oxaliplatin’s efficacy, ATG5, ATG7, and BECN1 are inhibited [85, 86].